RA Differentiation Enhances Dopaminergic Features, Changes Redox Parameters, and Increases Dopamine Transporter Dependency in 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells by Lopes, Fernanda et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1007/s12640-016-9699-0
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Lopes, F., da Motta, L. L., de Bastiani, M. A., Pfaffenseller, B., Aguiar, B. W., de Souza, L. F., ... Klamt, F.
(2017). RA Differentiation Enhances Dopaminergic Features, Changes Redox Parameters, and Increases
Dopamine Transporter Dependency in 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells.
NEUROTOXICITY RESEARCH, 1-15. https://doi.org/10.1007/s12640-016-9699-0
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1 
 
Title Page 
Title: RA-Differentiation Enhances Dopaminergic Features, Changes Redox 
Parameters and Increases Dopamine Transporter Dependency in 6-
Hydroxydopamine-Induced-Neurotoxicity in SH-SY5Y cells 
 
Authors: Fernanda M. Lopes1,2*, Leonardo L. da Motta1, Marco A. De 
Bastiani1, Bianca Pfaffenseller1, Bianca W. Aguiar1, Luiz F. de Souza3, 
Geancarlo Zanatta1, Daiani M. Vargas1; Patrícia Schönhofen1, Giovana F. 
Londero1, Liana M. de Medeiros1, Valder N. Freire4, Alcir L. Dafre3, Mauro A. A. 
Castro5, Richard B. Parsons2, Fabio Klamt1*. 
Filiation: 1Laboratory of Cellular Biochemistry, Department of Biochemistry, 
ICBS/UFRGS, 90035-003 Porto Alegre (RS), Brazil; 2Institute of Pharmaceutical 
Science, King’s College London, 150 Stamford Street, London SE1 9NH, UK; 
3Cellular Defenses Laboratory, Department of Biochemistry, Biological Sciences 
Centre, Federal University of Santa Catarina (UFSC), 88040-900 Florianopolis 
(SC), Brazil; 4Department of Physics at Federal University of Ceará (UFC), 
60455-760 Fortaleza (CE), Brazil; 5Bioinformatics and Systems Biology 
Laboratory, Federal University of Paraná (UFPR), Polytechnic Center, 81520-
260 Curitiba (PR), Brazil. 
*Correspondence to: MSc Fernanda M. Lopes & Prof. Fábio Klamt, PhD 
Laboratório de Bioquímica Celular (LBC), Departamento de Bioquímica, 
Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal do Rio 
Grande do Sul (UFRGS). 2600 Ramiro Barcelos St., Porto Alegre (RS), Brazil, 
90035-003. Phone: +55 51 3308-5556; FAX: +55 51 3308-5535, e-mail: 
fe.m.lopes@gmail.com / fabio.klamt@ufrgs.br  
2 
 
Abstract 
Research on Parkinson's disease (PD) and drug development is hampered by 
the lack of suitable human in vitro models that simply and accurately recreate 
the disease conditions. To counteract this, many attempts to differentiate cell 
lines, such as the human SH-SY5Y neuroblastoma, into dopaminergic neurons 
have been undertaken since they are easier to cultivate when compared to 
other cellular models. Here we characterized neuronal features discriminating 
undifferentiated and retinoic acid (RA)-differentiated SH-SYSY cells, and 
described significant differences between these cell models in 6-
hydroxydopamine (6-OHDA) cytotoxicity. In contrast to undifferentiated cells, 
RA-differentiated SH-SY5Y cells demonstrated low proliferative rate and a 
pronounced neuronal morphology with high expression of genes related to 
synapse vesicle cycle, dopamine synthesis/degradation, and of dopamine 
transporter (DAT). Significant differences between undifferentiated and RA-
differentiated SH-SY5Y cells in the overall capacity of antioxidant defenses 
were found; although RA-differentiated SH-SY5Y cells presented a higher basal 
antioxidant capacity with high resistance against H2O2 insult, they were two-fold 
more sensitive to 6-OHDA. DAT inhibition by 3α-bis-4-fluorophenyl-
methoxytropane and dithiothreitol (a cell-permeable thiol reducing agent) 
protected RA-differentiated, but not undifferentiated, SH-SY5Y cells from 
oxidative damage and cell death caused by 6-OHDA. Here we demonstrate that 
undifferentiated and RA-differentiated SH-SY5Y cells are two unique 
phenotypes and also have dissimilar mechanisms in 6-OHDA cytotoxicity. 
Hence, our data support the use of RA-differentiated SH-SY5Y cells as an in 
vitro model of PD.  This study may impact our understanding of the pathological 
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mechanisms of PD and the development of new therapies and drugs for the 
management of the disease. 
Keywords SH-SY5Y cells; retinoic acid; Parkinson’s disease; experimental 
model; 6-hydroxydopamine; dopamine transporter. 
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Introduction 
Dopaminergic degeneration found in Parkinson’s disease (PD) (Gibb 
1991) is mainly associated with oxidative stress (Fariello 1988) and 
mitochondrial dysfunction (Schapira et al. 1990). However, the functional 
changes operating during the initial stage of PD remain unknown (Mullin and 
Schapira 2015). The lack of understanding the molecular mechanisms of PD 
has many causes (Olanow et al. 2008; Olanow 2009), which one of them is 
attributed to the difficulty to reproduce the complex physiological features of a 
human dopaminergic neuron in vitro (Schüle et al. 2009; Bal-Price et al. 2010).  
Hence, there are limited reliable neuronal in vitro cell models to study PD 
pathophysiological mechanisms (Radio and Mundy 2008; Haggarty and Perlis 
2014).  
In this context, the human neuroblastoma cell line SH-SY5Y is the most 
used in vitro model of dopaminergic neurons (Xie et al. 2010) because not only 
it expresses the catecholamine synthesis machinery, but also it is easy to 
cultivate when compared with another in vitro models (e.g. primary culture and 
inducible pluripotent stem cells –iPS) (Biedler et al. 1978; Kovalevich and 
Langford 2013). Even though these cells are widely used in PD research, they 
are epithelial cells and do not present neuronal properties such as a terminal 
post-mitotic state and the expression of synaptic proteins (Radio and Mundy 
2008). Interestingly, the in vitro differentiation induced by retinoic acid (RA) of 
this cell line into a neuron-like phenotype was established more than 30 years 
ago (Påhlman et al. 1984).  
However, there is no consensus which differentiation protocol is more 
suitable for this cells line. The scientific literature shows a divergence not only in 
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serum concentration (1-10% FBS), which neurotrophin to be used (e.g. RA, 
BDNF, TPA), but also in differentiation length (4-12 days). Hence, depending on 
the protocol used, there are several discrepancy among findings regarding 
neuronal and dopaminergic markers (e.g. tyrosine hydroxylase –TH and 
dopamine transporter –DAT) (Presgraves et al. 2004; Cheung et al. 2009; 
Agholme et al. 2010; Lopes et al. 2010; Korecka et al. 2013). This brings 
discussion whether SH-SY5Y cells must be differentiated (Luchtman and Song 
2010; Xie et al. 2010). 
Furthermore, different protocols also may cause changings in cell 
susceptibility to neurotoxins, such as 6-hydroxydopamine (6-OHDA) (Cheung et 
al. 2009; Lopes et al. 2010; Forster et al. 2016). In vivo, it is widely accepted 
that this toxin enters into the dopaminergic neuron via DAT and causes a 
massive oxidative stress (Ljungdahl et al. 1971). However, 6-OHDA mechanism 
of action is still controversial for in vitro studies.  Although DAT inhibitors 
provide a partial protection against 6-OHDA toxicity towards primary 
dopaminergic neurons (Cerruti et al. 1993; Abad et al. 1995), many lines of 
evidence showed no protection in undifferentiated SH-SY5Y cells from cell 
death induced by this toxin (Storch et al. 2000; Izumi et al. 2005; Hanrott et al. 
2006). Regarding RA-differentiated SH-SY5Y cells, no study showed the effect 
of DAT inhibition in 6-OHDA-induced cell death.   
Even though with the emergence of new, more physiologically relevant 
models such as iPS as in vitro models for PD (Hartfield et al. 2014), it is clear 
that the majority of studies have been undertaken using cell lines such as SH-
SY5Y due to considerations such as availability of iPS and the necessary 
expertise in their differentiation into dopaminergic neurons (Filograna et al. 
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2015; Forster et al. 2016; Lin and Tsai 2016). Hence, an understanding of the 
potential differences in SH-SY5Y cell line RA-differentiated and undifferentiated 
states and their response to 6-OHDA are imperative as this remains the most 
commonly-used in vitro model (Kovalevich and Langford 2013).  
In the present work, we aimed to validate a differentiation protocol 
previously described by our research group (Lopes et al. 2010) comparing 
undifferentiated and RA-differentiated SH-SY5Y cells regarding gene 
expression of important cellular networks related to dopaminergic neuronal 
machinery, morphology, redox metabolism and 6-OHDA cytotoxicity. To further 
investigate 6-OHDA operating mechanisms in both models, DAT inhibition and 
pre-treatment with thiol reducing agents were performed. Here we demonstrate 
critical differences between models, such as DAT dependency of 6-OHDA-
induced cell death in RA-differentiated SH-SY5Y cells. 
Materials and Methods 
Cell Culture 
Human neuroblastoma cell line SH-SY5Y (ATCC, Manassas, VA, USA) 
was maintained in a 1:1 mixture of Ham’s F12 and Dulbeco Modified Eagle 
Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Cripion®, São Paulo, SP, Brazil), 2 mM of glutamine, 100 U/mL of 
penicillin/streptomycin and antimycotic (Thermo Fisher Scientific®, cat. 
#10378016, Waltham, MA, USA) in a humidified atmosphere of 5% of CO2 at 
37ºC.  
In our cellular differentiation protocol (as described in Fig.1) only 
attached cells were maintained and floating cells were discarded. 3 X104 
cells/cm2 were seed in 10% FBS medium. After 24 hours (day 1), medium was 
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replaced with medium in which the FBS concentration was reduced to 1% and 
supplemented with 10 µM of RA (all-trans-retinoic-acid, Enzo® - East 
Farmingdale, NY, USA), and incubated for 7 days. At the day 4, the medium 
was replaced, and at the day 7, cells were harvested and used for experiments.  
It is important to note that successful differentiation depends upon (at 
least) 3 factors: (i) the confluence of the cells in day 1 must be around 75% 
(higher confluence inhibits neurite outgrowth, and lower confluence leads SH-
SY5Y cells to detach); (ii) the cell medium should only be used for a maximum 
of 2 weeks to avoid glutamine decomposition; and (iii) RA powder is diluted in 
absolute ethanol to prepare the stock solution. The concentration of this solution 
was determined using EM (351 nm) = 45000 at the day of the medium 
replacement (i.e. days 1 and 4) to control any changes in the concentration that 
may occur during storage (Lopes et al. 2010; Sharow et al. 2012).  
RNA isolation and microarray assay 
 Cells were harvested and the RNA was isolated using TRIzol Reagent 
(Thermo Fisher Scientific®, Waltham, MA, USA) following by purification 
(Qiagen RNeasy Mini Kit #74 104 and #79 254 - Free RNase DNase Set 
Qiagen,Hilden, Germany). Microarray analysis was performed using the chip 
GeneChip® PrimeView™ Human Gene Expression Array (Affymetrix™). The 
samples were collected at the day 0 (undifferentiated cells) and day 7 (RA-
differentiated cells) (Fig. 1) and raw data was deposited on GEO repository 
(GEOID: GSE71817).   
Gene Set Enrichment Analysis (GSEA) and expression values 
Four genes networks were analyzed in both undifferentiated and RA-
differentiated SH-SY5Y cells: cell cycle, synapse vesicle cycle, dopaminergic 
synapse and antioxidant (extracted from KEGG platform) 
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(Http://www.genome.jp/kegg/pathway.html 2016). Gene set enrichment analysis 
was used to identify genes that contribute to global changes in expression 
levels in a given microarray dataset comparison. GSEA considers experiments 
with genome-wide expression profiles from two classes of samples (e.g. RA-
differentiated cells vs. undifferentiated). Genes were ranked based on the 
correlation between their expression and the class distinction. Given a prior 
defined network (e.g. synaptic vesicle cycle), the GSEA determines if the 
members of these sets of genes are randomly distributed or primarily found at 
the top or bottom of the ranking (Subramanian et al. 2005).  
To access the logarithm of gene expression, raw CEL files were 
analyzed using the R/Bioconductor pipeline. The data was normalized by 
Robust Multi-array Average (RMA) using the AFFY package, log (base 2) 
transformed, and batch-corrected with ComBat using the SVA package. 
Cell cycle and cellular growth  
DNA composition was measured using propidium iodide (PI) (Thermo 
Fisher Scientific®, cat. # P3566, Waltham, MA, USA), flow cytometry (BD 
AccuriTM C6 Flow Cytometer, USA).  The results were express as percentage of 
cells in each cell cycle phase (G0/G1, S, G2/M). Cellular proliferation was 
measured by cell counting using a Neubauer Chamber.  Undifferentiated cells 
reach the confluency at the day 4, forming a monolayer. After this, cells 
continued to proliferate, as shown in Fig. 2a, but as floating cells.  
Neurite Density  
Neurite density was evaluated by immunofluorescence. Cells were 
washed with PBS, fixed with methanol/acetone solution (1:1) for 20 minutes in 
room temperature and permeabilized with PBS/Tween 0,2%. The blocking was 
performed with 1% BSA solution for 1 h in room temperature. Then, cells were 
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incubated with anti-βIII tubulin antibody (Alexa 488-conjugated – Abcam®, cat. # 
ab204605, Cambridge, UK, - dilution: 1:250) for 2 hours in room temperature 
and with Nuclear dye DAPI (Thermo Fisher Scientific®, cat. # D1306, Waltham, 
Massachussets, USA- dilution: 0.25 µg/µL) for 5 min. Randomly selected 
Images were captured using an Olympus IX70 inverted microscope and 
analyzed with NIS-elements software. Neurite density was assessed using the 
AutoQuant Neurite software (implemented in R), and expressed as arbitrary 
units (A.U.) (Schönhofen et al. 2015).  
Dopamine immunoreactivity  
Dopamine reactivity was evaluated using an anti-dopamine antibody 
(Abcam®, cat. # ab6427, Cambridge, UK dilution: 1:250) followed by incubation 
with Alexa 488-conjugated-antibody (Thermo Fisher Scientific®, cat. #A11008, 
Waltham, MA, USA- A11008 - dilution: 1:500). Randomly selected images were 
captured using an EVOS® FLoid® Cell Imaging (Korecka et al. 2013). 
Cytotoxicity parameters 
Undifferentiated and RA-differentiated SH-SY5Y cells were treated for 24 
hours with 6-OHDA and H2O2. Cell viability were analyzed using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT- Sigma®, cat. # 
M5655) reduction assay as previously described (Lopes et al. 2010).  
Oxidative stress parameters  
We evaluated the redox status in both undifferentiated and RA-
differentiated SH-SY5Y cells by measuring: reduced thiol and reduced 
glutathione (GSH) levels as well as the following antioxidant enzymes activities: 
Glutathione Peroxidase (GPx), Catalase (CAT), Superoxide Dismutase (SOD), 
Thioredoxin Reductase (TrxR), Glutathione Reductase (GR), Glutathione-S-
transferase (GST) as described previously (Lopes et al. 2012). H2O2 generation 
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was measured using AmplexRed® (Thermo Fisher Scientific®, cat. # a12222, 
Waltham, MA, USA). 
Reducing thiol agents treatment  
The role of reducing agents in 6-OHDA-cytotoxicity was assessed via 
pre-treatment with Dithiothreitol (DTT)(Sigma®, cat. # D0632) or tris(2-
carboxyethyl)phosphine (TCEP) (Sigma®, cat. # C4706) in both cell models for 
1 hour in 37ºC. Cells were then incubated with the median toxic dose (TD50) 
dose of 6-OHDA. The cytotoxicity was analyzed using MTT reduction. 
DAT immunocontent  
To evaluate changes in DAT immunocontent during the RA-differentiation 
process, western blot analysis was performed using anti-DAT antibody (Santa 
Cruz® Biotechnology, cat. # 9299, Dallas, TX, USA - dilution: 1:1000) and rabbit 
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (Abcam®, 
cat. # ab9485, Cambridge, UK - dilution 1:5000) as loading control.  
Molecular Docking 
The calculations performed in this study have taken full advantage of the 
X-ray crystal structure of the Drosophila melanogaster DAT (PDB ID 4M48) at 
3.0 Å of resolution (Penmatsa et al. 2013).  
Molecular docking was performed using Autodock4 and the protocol 
adopted validated through the redocking of nortriptyline in the DAT binding site, 
as describe elsewhere (Halperin et al. 2002; Mohammad et al. 2008), which 
was employed to obtain the molecular structures of dopamine, 6-OHDA, p-
quinone and DATi (DATi = 3α-bis-4-fluorophenyl-methoxytropane) (Tocris®, cat. 
#0918, Avonmonth, Bristol, UK) for docking input. Upon completion, a thousand 
poses were obtained (50 poses per output) and clustered within a RMSD 
tolerance of 1.0 Å using Autodock Tools The best results obtained were based 
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upon visual inspection and the calculated binding energy. Binding energy (EOPT) 
was recalculated, using Forcite code, through the equation “EOPT = EDAT + L - 
(EDAT + EL)” where EDAT + L is the total energy of the system formed by 
ligand bond in DAT; EDAT is the total energy of the DAT alone, while EL is the 
total energy of the ligand molecule alone. 
DAT pharmacological inhibition  
To investigate the DAT dependency of 6-OHDA-induced cell death in 
both models, cells were pre-incubated for 30 minutes with 20 µM of DATi 
(Tocris®, cat. #0918, Avonmonth, Bristol, UK). Following this, cells were 
exposure to TD50 6-OHDA for 24 hours (Lopes et al. 2010). Cell viability was 
assessed using MTT assay. H2O2 generation was measured using 
AmplexRed®. 
Statistical Analysis 
Data were expressed as means ± S.D of at least 3 independent 
experiments carried out in triplicate, and P-values were considered significant 
for p < 0.05. Differences within the experimental groups were determined by 
Student’s t-test or one-way analysis of variance (ANOVA). Comparison among 
means was carried out using Newman-Keuls multiple comparisons test as post 
hoc (GraphPad® Software 5.0).  
Results 
RA-differentiation protocol induces neuronal features in SH-SY5Y cells 
PD-target cells are neurons derived from substantia nigra pars compacta, 
which are specialized cells that process and transmit information through 
electrical and chemical synapses, with stellate morphology and do not undergo 
to cell divisions (Kandel 2013). To evaluate these relevant features to mimic 
more accurately the neuronal cell physiology, we explored the effect of RA-
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differentiation protocol on cell growth, morphology and the expression of gene 
sets associated with cell cycle and synapse vesicle cycle (protocol description 
in Fig. 1).  
Here we showed a significant decrease in the proliferation rates of RA-
differentiated SH-SY5Y cells (Fig. 2a) (n = 3; p < 0.001) mainly associated with 
a decrease in S phase in combination with an arrest in G2-M (Fig. 2b) (n = 3; p 
< 0.001). Further, we investigated gene expression of the cell cycle network 
(KEGG pathways entry #hsa04110) using microarray analysis in 
undifferentiated and RA-differentiated cells. Although no statically significant 
differences were observed between the two phenotypes, there are genes 
associated with G2-M arrest, such asGDD45G and SMAD3 (Herrup and Yang 
2007), upregulated in RA-differentiated SH-SY5Y cells as shown in 
Supplementary Fig. 1 (Electronic Supplementary Material).  
Upon the decrease in proliferation rate and cell cycle arrest, a significant 
change in morphology with increased neurite density was verified in RA-
differentiated cells (Fig. 2c,d) (n = 3; p < 0.0001), suggesting a change from 
epithelial (as defined by ATCC for SH-SY5Y cells) 
(www.atcc.org/Products/All/CRL-2266.aspx) to a stellate neuronal morphology. 
After morphological characterization, we analyzed which cellular model 
possessed the appropriate molecular machinery to support the synaptic 
transmission, using the synaptic vesicle cycle gene list (extracted from KEGG 
pathways entry #hsa04728). We found a significant enrichment of this gene set 
in RA-differentiated, compared to undifferentiated, SH-SY5Y cells (Fig. 2e,f) (n= 
4; p < 0.05). Enriched genes are listed in Table 1.  
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RA differentiation potentiates dopaminergic features in SH-SY5Y cells 
After studying the differences in general neuronal properties obtained 
with from RA-differentiation protocol, we investigated dopaminergic features of 
both phenotypes of SH-SY5Y cells. At first, we evaluated global differences in 
gene expression of the dopaminergic synapse network, where we found no 
significant differences between the two models (Fig. 3a). However, there are 
genes upregulated in RA-differentiated cells listed in Supplementary Table 1, 
(Electronic Supplementary Material).    
Using differential gene expression analysis, we verified the expression 
levels of the most common dopaminergic markers (Korecka et al. 2013), 
associated with catecholamine synthesis (Dopa decarboxylase- DDC, GTP 
cyclohydrolase- GCH1 and TH), degradation (monoamine oxidase A and B -
MAOA, MAOB-, Catechol-O-methyltransferase-COMT), and synaptic function 
(Vesicular monoamine transporter 1 and 2- SLC18A1, SLC18A2, dopamine 
transporter- SLC6A3, dopamine receptor D2- DRD2). Both models present the 
same level of expression in all genes studied except for DR2, GHC and 
SLC18A1, which have higher expression in the RA-differentiated cells (Fig. 3b). 
Lastly, dopamine immunocontent was investigated using an 
immunocytochemical approach in both SH-SY5Y phenotypes. In Figure 3c, we 
confirmed that both models have immunochemical detection of this 
neurotransmitter. Hence, in spite of both models of SH-SY5Y cells present 
dopamine content, neuronal dopaminergic features are potentiated after RA-
differentiation (e.g DRD2 and SLC18A1).   
RA-differentiation induces changes in oxidative status and 6-OHDA-mediated 
neurotoxicity in SH-SY5Y cells 
Due to the pivotal role played by reactive species in PD (Fariello 1988), 
the endogenous machinery responsible for the basal redox status should be 
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characterized when establishing any relevant in vitro cell model of PD. To do 
so, we firstly evaluated the gene expression levels of the human antioxidant 
network (according to KEGG pathways). There were no differences in gene 
expression in antioxidant network. However, some antioxidant genes were 
upregulated in RA-differentiated cells (e.g. GPX3, TMX4 and GRLX) (Fig. 4a).  
To better characterize these redox differences, we evaluated the activity 
of several enzymes involved in first line antioxidant defenses and the level of 
non-enzymatic antioxidant defenses in both SH-SY5Y phenotypes. Our in vitro 
validation revealed that RA-differentiated cells have higher antioxidant enzymes 
activities and lower levels of H2O2 production (Table 2).  
After investigate the basal redox metabolism in undifferentiated and RA-
differentiated SH-SY5Y cells, we aimed to examine their susceptibility to 
oxidative stress induced by H2O2 and 6-OHDA. RA-differentiated SH-SY5Y cells 
were more resistant to H2O2, yet they were two-fold more susceptible to 6-
OHDA cytotoxicity (Table 2). It is well known that 6-OHDA toxicity acts via the 
induction of oxidative stress, however the higher endogenous antioxidant 
capacity observed was not able to protect RA-differentiated cells from the cell 
death, suggesting a dissimilar mechanism of 6-OHDA detoxification in this 
cellular model.  
The role of thiols in 6-OHDA-induced cell death in undifferentiated and RA-
differentiated SH-SY5Y cells 
Previous data have shown that 6-OHDA uptake is not an essential 
process and the auto-oxidation occurs extracellularly in undifferentiated SH-
SY5Y cells (Storch et al. 2000; Hanrott et al. 2006; Iglesias-González et al. 
2012), suggesting that this toxin has different mechanisms from animal and 
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primary culture models. Hence, in order to understand our previous results 
regarding the susceptibility of 6-OHDA in RA-differentiated cells, we evaluate 
the role of cell-permeable and cell-impermeable reducing agents in 6-OHDA-
induced-cell-death.  
We first pre-incubated undifferentiated and RA-differentiated cells with 
two thiol reducing agents TCEP (a cell-impermeable compound) and DTT (a 
cell-permeable molecule), before challenging cells with 6-OHDA (Fig. 4b,d) 
(Hsu et al. 2005). Interestingly, no differences were found between both cellular 
models when TCEP were used to protect cells against 6-OHDA-oxidant insult 
(Fig. 4c). On the other hand, DTT was able to prevent 60% of 6-OHDA-
dependent cytotoxicity in RA-differentiated cells (Fig. 4e) (n = 3; p < 0.0005), in 
contrast to only 24% in undifferentiated cells, indicating that, in RA-differentiated 
cells, an intracellular oxidation step of the neurotoxin is associated with the cell 
death caused by 6-OHDA (Fig 4b, F (3,8) = 126.5, n = 3; p < 0.0001). 
The role of DAT in 6-OHDA-induced-cell death in undifferentiated and RA-
differentiated SH-SY5Y cells 
To investigate more accurately the role of intracellular auto-oxidation, we 
evaluated the role of DAT in the toxicity induced by 6-OHDA in both cellular 
models because the activity of this transporter is fundamental for toxin uptake. 
In Figure 5a shows an increase in DAT immunocontent in RA-differentiated 
cells (n = 3; p < 0.01).  
We then verified whether the inhibition of this transporter interfered in the 
cell death caused by 6-OHDA. First, we examined how DATi and 6-OHDA 
interacts with DAT by using molecular docking followed by classical refinement 
of geometries (Fig. 5b), and compared the binding energy (EOPT) of those 
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compounds with the corresponding values obtained for dopamine and p-
quinone (Supplementary Fig. 2 and Supplementary Table 2 for the raw docking 
data in Electronic Supplementary Material). Our data suggests that DATi inhibits 
DAT by preventing substrate binding and stabilizing the outward-open 
conformation. Furthermore, we found that dopamine, DATi, p-quinone and 6-
OHDA, all compete sterically for the same binding site via the spatial blockage 
of Asp46 residue (Asp79 in DAT from Homo sapiens). This steric blockage of 
the same binding site demonstrates a competitive inhibition mechanism of 
action for DATi (Fig. 5b). Due to the lower ligation energy of DATi for DAT in 
comparison to p-quinone and 6-OHDA, but higher for dopamine, our docking 
data showed that DATi blocks completely the interaction of dopamine with DAT, 
but only partially p-quinone and 6-OHDA (Supplementary Table 2 in Electronic 
Supplementary Material). Thus, it suggests that DATi inhibits DAT by preventing 
substrate binding and stabilizing the outward-open conformation. 
Based on these findings, we pharmacologically inhibited DAT in both 
cellular models via incubation with DATi prior to challenging cells with 6-OHDA. 
Our data showed that DAT inhibition resulted in a significant decrease in cell 
death (41%) (Fig. 5f) and H2O2 production (48%) (Fig. 5d) by 6-OHDA treatment 
only in RA-differentiated cells with no effect observed in undifferentiated cells, 
suggesting a specific role played by DAT in the cell death caused by this 
neurotoxin in the neuronal phenotype (Fig. 5c, F (3,12) = 9.571, n =3; p < 0. 01) 
(Fig. 5e, F (3,8) = 201.4, n = 3; p < 0.0001). 
Discussion 
The difficulty in mimicking neuronal features in vitro has always been an 
issue in neurosciences studies, thus the development of more suitable models 
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is necessary since they are fundamental to study molecular mechanism of 
neurodegenerative disease, such as PD. In this regard, the most in vitro 
experimental model used for PD is the human neuroblastoma SH-SY5Y cell 
because they express dopaminergic markers and are easy to cultivate when 
compared to other models (Xie et al. 2010; Kovalevich and Langford 2013). We 
previously established a catecholaminergic differentiation protocol for this cell 
line (Lopes et al. 2010). Here we focused in explore neuronal features in both 
cellular models. 
There are many lines of evidence showing the effect of RA-differentiation 
in SH-SY5Y regarding the evaluation of proliferation rates (Ross 1996; Pezzini 
et al. 2016; Kunzler et al. 2016). Previous studies have demonstrated that RA-
induced differentiation can cause cell cycle arrest either in G1/G0 phase or in 
G2/M phase and a decrease in proliferation rates, which leads to terminal 
differentiation of neuroblastoma cells (Qiao et al. 2012; Hämmerle et al. 2013).  
We verified decreased cellular growth in RA-differentiated cells was 
associated with a decrease in S phase in combination with G2-M arrest (Fig. 
2b). This data corroborates with our findings regarding gene expression of the 
cell cycle network. Genes upregulated in RA-differentiated cells are associated 
with cell cycle arrest, for instance, cyclin-dependent protein kinases (CDK) 
inhibitors (e.g. p18, p19, p21 and p27) and to G2-M arrest, such as GDD45G 
and SMAD3 (Herrup and Yang 2007) (Summarized in Supplementary Fig. 1 in 
Electronic supplementary material). Moreover, the cell cycle arrest in G2-M is 
commonly found in neurodegenerative diseases such and PD, where some 
populations of neurons complete DNA synthesis and are able to pass through 
the S phase, but are arrested at the G2/M (Frade and Ovejero-Benito 2015). 
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Another important neuronal parameter is cellular morphology. Neurons 
present neurites, which refers to axons and dendrites extended by neuronal cell 
lines, thus their quantification is an important morphological parameter of 
neuronal differentiation (Radio and Mundy 2008; Bal-Price et al. 2010). Here, 
we showed an increase in neurite density in RA-differentiated cells, 
representing a significant advantage of this cellular model, since these 
structures form synapses and can be used as an endpoint in neurotoxicological 
evaluations (Lopes et al. 2012).  
Besides low proliferation rates and stellate morphology, dopaminergic 
neuronal cells process their information through chemical synapses. The 
biological event related to neurotransmitter release is the synaptic vesicle cycle 
(Kandel 2013). This pathway consists of exocytosis followed by endocytosis 
and recycle (Rizo and Xu 2015). At first, vesicles are loaded with 
neurotransmitters, which require the presence of an active transporter along 
with a proton pump to provides the required pH and electrochemical gradients. 
Fundamental to this is the role of H+-ATPase transporters and solute carriers 
such as SLC18A1, SLC18A3 and SLC17A8 (Beyenbach and Wieczorek 2006). 
Once the vesicles are loaded, they are tethered near to the release sites, after 
which vesicles are primed before being ready to undergo fusion. Genes 
involved in this process include UNC13, RIMS1 and syntaxin (Madison et al. 
2005). The primed vesicles subsequently undergo fusion processes that are 
regulated by SNARE proteins, such as SNAP-25, NSF and complexins (Hu et 
al. 2002). Finally, the synaptic vesicles incorporated to the plasma membrane 
are retrieved by endocytosis, a process which involves many proteins, e.g. 
dynamins and clathrins (Takei et al. 1996). Our results demonstrated that all of 
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these genes were up-regulated in RA-differentiated cells (Fig. 2e,f; Table 1), 
suggesting that this model has appropriate machinery to support synapses.  
Our data point to highly diverse phenotypes presented by both cellular 
models. Undifferentiated cells exhibited characteristics typical of a tumoral 
phenotype, namely epithelial morphology and high proliferation rates. In 
contrast, RA-differentiated SH-SY5Y cells were characteristic of a neuronal 
phenotype, presenting low proliferation rates, a pronounced neuronal 
morphology and an enrichment of the molecular machinery responsible for 
synaptic function.  
After neuronal characterization, we aimed to verify if both cellular models 
have dopaminergic phenotype, since these cells are the most affected neurons 
in PD. Here, we demonstrated that both phenotypes of SH-SY5Y cells 
expressed the dopaminergic machinery. This was expected since it is well 
known that neuroblastoma cancers (as the primary tumor that SH-SY5Y cells 
were isolated from) produce catecholamines, mainly because they have low 
levels of dopaminergic markers (Howman-Giles et al. 2007). As such, 
undifferentiated cells are commonly used as PD model (Xie et al. 2010).  
Previous data showed that the differentiation process does not lead to 
increase of dopaminergic markers in SH-SY5Y cells, which it brings the 
discussion whether they need to be differentiated (Luchtman and Song 2010). 
On the other hand, many lines of evidence showed that RA-differentiated cells 
increase their expression of these dopaminergic markers, such as TH and DAT 
(Påhlman et al. 1984; Lopes et al. 2010; Filograna et al. 2015). These 
discrepancies in the literature might be attributable to the varying differentiation 
protocols used, since there are differences between them, such as duration, cell 
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densities, serum concentration and differentiation agent (e.g. RA, staurosporine, 
BDNF) (Cheung et al. 2009; Agholme et al. 2010; Lopes et al. 2010; Filograna 
et al. 2015). 
Hence, our results show that both models have the machinery necessary 
to synthetize and release dopamine. Although no global statistically significant 
differences were observed between the two phenotypes, there are genes 
associated with dopamine synthesis regulation (PKA, MAPK, CAMKII and 
PP2A) significantly upregulated in RA-differentiated SH-SY5Y cells (Fig. 3a; 
Supplementary Table 1) (Dunkley et al. 2004; Daubner et al. 2011). Moreover, 
differential expression showed significant increase in GHC1, DRD2 and SLC18, 
three important catecholaminergic markers. These findings demonstrated that 
RA –differentiation potentiates the dopaminergic phenotype, which validates our 
protocol and its potential use as PD in vitro model. 
Since dopaminergic neurons are exposed to a chronic oxidative damage, 
mostly attributed to the high levels of iron present in SNpc, the hydroxyl radical 
(HO•) produced by dopamine metabolism (Zhou et al. 2010), oxidative stress is 
thought to causally contribute to the pathogenesis of progressive 
neurodegeneration observed in PD (Fariello 1988). Hence, oxidative stress 
parameters should be investigate when establishing in vitro cell model of PD. 
Our in vitro validation revealed that both models have thioredoxin and 
glutathione antioxidant systems as the main antioxidant defense. The H2O2 
detoxification in neuronal cells is catalyzed primarily by thioredoxin and 
glutathione systems, which are the most important antioxidants in the brain 
(Lopert et al. 2012; Garcia-Garcia et al. 2012), hence we found that both 
models mimic the oxidative neuronal profile.   
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Moreover, we showed that RA-differentiated cells presented a higher 
basal antioxidant capacity and decrease of H2O2 production. At first, these data 
seem controversial because neuronal cells presents low antioxidant levels 
(Halliwell 2006; Dexter and Jenner 2013), hence the differentiated cells do not 
represent accurately the physiology of dopaminergic neurons. However, here 
we are comparing the neuronal and tumoral phenotypes. The oxidative 
environment of the undifferentiated cells could be explained by its proliferative 
profile since H2O2 is fundamental for cellular growth (Policastro et al. 2004; Sies 
2014). 
Here the most intriguing observation was that RA-differentiated SH-SY5Y 
cells were more resistant to H2O2, yet were more susceptible to 6-OHDA 
cytotoxicity (Table 2). Cellular resistance to H2O2 in the neuronal phenotype can 
be explained by the elevated basal antioxidant capacity. Since the RA-induced 
differentiation decreases levels of TrxR and GSH, this may suggests a role of 
these antioxidants in 6-OHDA detoxification, as previously described (Soto-
Otero et al. 2000; Lopert et al. 2012). Hence, the resistance to 6-OHDA found in 
undifferentiated cells can be explained, at least in part, by the high GSH levels 
presented in the tumoral phenotype.  
It is widely elucidate that 6-OHDA is taken up by dopaminergic neurons 
via DAT (Tranzer and Thoenen 1973) and auto-oxidation process occurs 
intracellularly (Glinka et al. 1997) manly because the toxicity can be blocked by 
DAT inhibition (González-Hernández et al. 2004). On the other hand, previous 
data have shown that 6-OHDA uptake is not an essential process and the auto-
oxidation occurs extracellularly in undifferentiated cells (Izumi et al. 2005). Here 
we found that part of the oxidative dysfunction caused by 6-OHDA involves the 
22 
 
uptake of the neurotoxin (or some metabolite, such as p-quinones) presumably 
followed by intracellular auto-oxidation in RA-differentiated cells. 
Further investigation about intracellular oxidation demonstrated that 
pharmacological DAT inhibition decreases H2O2 production and cellular death 
caused by 6-OHDA only in RA-differentiated SH-SY5Y cells. Regarding 
undifferentiated SH-SY5YS cells, DAT inhibition did not protect the cells, 
possibly because these cells have low levels of DAT (Presgraves et al. 2004), 
which corroborates with previous results (Storch et al. 2000; Izumi et al. 2005).  
These results may impact the development of new therapies and drugs 
for the management of the disease. To date, PD is still an incurable disease 
and we have failed to find neuroprotective compounds (Olanow et al. 2008). 
The main reason to this issue is the lack of understanding of the initial steps 
underlying dopaminergic degeneration (Obeso et al. 2010). Although PD is 
considered a complex disorder where many mechanisms are involved (e.g. 
protein aggregation, mitochondria dysfunction and oxidative stress), the 
common pathology found in all PD cases is the dopaminergic degeneration 
(Gibb 1991). Hence, the development of better dopaminergic cell models and 
the understanding of dopaminergic cell physiology are essential for PD 
research. In spite of many lines of evidence have shown that undifferentiated 
SH-SY5Y cells are dopaminergic-producing cells and easy to cultivate 
(Presgraves et al. 2004; Cheung et al. 2009; Agholme et al. 2010; Lopes et al. 
2010), they do not reproduce both dopaminergic physiology and 6-OHDA-
induced-cell death mechanisms of in vivo or primary cell culture studies. Thus, 
SH-SY5Y cells are the target of many discussions whether it should be used in 
PD research. Our data suggests, for the first time, the role of toxin uptake by 
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DAT in RA-differentiated cells, showing that an easy cellular model can mimic, 
at least part, 6-OHDA-induced cell death in vivo.  
Conclusions 
Undifferentiated and RA-differentiated SH-SY5Y cells are two unique 
phenotypes which can be distinguished by differences found in cells 
morphology, cell growth, neuronal and dopaminergic marker expression and 
redox metabolism. These features may contribute towards two different 
mechanisms of action for 6-OHDA-cytotoxicty observed in both models. In the 
neuronal phenotype, we demonstrated DAT dependency in 6-OHDA-induced 
cell death, which is likely related to their dopaminergic phenotype. Many 
previous studies have used undifferentiated cells as a PD model to study 
molecular mechanisms, to test potential drugs for the treatment of this disease 
and also to evaluate 6-OHDA’s mechanisms of action and cellular targets. 
However, our data demonstrate that undifferentiated cells does not possess 
neuronal properties, which can create significant bias in such studies, and may 
have contributed, at least in part, to the limitations in our understanding of PD 
pathophysiology and, consequently, the lack of potential drugs to treat the 
disease. Hence, our data support the use of RA-differentiated cells as an in vitro 
model of PD.   
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Figure Captions 
 
Fig 1 Protocol design of the RA-induced differentiation. At day 0, exponentially 
growing SH-SY5Y cells were cultured in cell medium containing 10% FBS. After 
24 hours (day 1), the medium was removed and fresh medium containing 1% 
FBS and 10 µM RA (differentiation medium) was added. 3 days later (day 4), 
the differentiation medium was replaced with fresh differentiation medium. At 
day 7, SH-SY5Y cells were used in experiments  
Fig. 2 Neuronal characterization of undifferentiated and RA-differentiated SH-
SY5Y cells (A) Cellular growth in undifferentiated and RA-differentiated cells. 
(B) Cell cycle analysis. Representative image of the cell cycle analysis in 
undifferentiated cells and RA-differentiated cells, in which results were 
expressed as percentage of cells in each cell cycle phase (G0/G1, S, G2/M). 
Neurite density was evaluated by immunofluorescence. (C) Representative  
images of immunocytochemical detection of tubulin in undifferentiated and RA-
differentiated SH-SY5Y cells. (D) Quantification of the neurite density per cell 
body using AutoQuant Neurite software. Expression of synaptic vesicle cycle 
network in undifferentiated and RA-differentiated SH-SY5Y cells. (E) STRING 
representation of synaptic vesicle cycle network gene interactions and 
landscape analysis, generated with ViaComplex® V1.0. Color gradient (Z-axis), 
demonstrating elevated expression of this network in 7-day-RA-differentiated, 
compared to undifferentiated, SH-SY5Y cells. P value refers to bootstrap 
analysis comparing cell lines. (F) Enrichment analysis used to identify the genes 
that contributed individually to the global changes in expression levels observed 
in RA-differentiated cells in the syntactic vesicle cycle network. Data are 
presented as mean ± SD of four independent experiments (n = 4), each carried 
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out in triplicates. *P < 0.05 (Student’s t-test). Transcripts obtained as described 
in Material and Methods section. Nominal p value of enrichment analysis 
obtained from GSEA (p < 0.05)  
Fig. 3 Dopaminergic characterization of undifferentiated and RA-differentiated 
SH-SY5Y cells. (A) Enrichment analysis used to identify the genes that 
contributed individually to the global changes in expression levels observed in 
RA-differentiated cells in the dopaminergic synapse network using GSEA. (B) 
Differential expression levels of pre-synaptic dopaminergic markers in 
undifferentiated and RA-differentiated cells. (C) Immunocytochemical detection 
of dopamine. Representative fluorescence microscopy images of 
undifferentiated and RA-differentiated SH-SY5Y cells. Data are presented as 
mean ± SD of four independent experiments (n = 4), each carried out in 
triplicates (n= 4). *P < 0.05 (Student’s t-test).  
Fig. 4 Redox characterization of undifferentiated and RA-differentiated SH-
SY5Y cells. (A) Enrichment analysis used to identify the genes that contributed 
individually to the global changes in expression levels observed in RA-
differentiated cells in the antioxidant network using GSEA. The role of cell-
impermeable (B) and cell-permeable (D) thiol-reducing agents pre-treatment in 
6-OHDA-induced cell death in undifferentiated and RA-differentiated SH-SY5Y 
cells. The results were expressed as a percentage of the control ± SD. 
Significant differences are expressed by letters, where equal letters represent 
no significant differences and different letters represent significant differences 
(P < 0.05) (one-way analysis of variance). (C,E) Analysis of the inhibition of 6-
OHDA-induced cell death for each thiol-reducing agent in both cellular models. 
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Data are presented as mean ± SD of four independent experiments (n = 4), 
each carried out in triplicates. *P < 0.05 (Student’s t-test) 
Fig. 5 Evaluation of the role of DAT in 6-OHDA-induced cell death in 
undifferentiated and RA-differentiated SH-SY5Y cells (A) Changes in DAT 
immunocontent (dopaminergic cell marker) in response to RA-differentiation 
was evaluated using Western blot. Representative densitometric analysis of 
bands and immunoblot of DAT, using GAPDH as loading control. Results were 
calculated and expressed as mean ± SD of densitometric units (n = 4). *P < 
0.01 (Student’s t-test). (B) Superposition of DATi and 6-OHDA into the binding 
site of DAT, showing how 6-OHDA is spatially blocked from forming a salt 
bridge with Asp46. (C) Evaluation of DAT inhibition in the rate of H2O2 
production, DAT-dependent H2O2 generation and (E) cell death in 
undifferentiated and RA-differentiated SH-SY5Y cells challenged with 6-OHDA. 
Cells were treated for 30 minutes with DATi prior to incubation with LD50 
concentration of 6-OHDA for 24 hours. Cell viability was evaluated using the 
MTT reduction assay and results were expressed as percentage of untreated 
cells. Significant differences are expressed by letters, where equal letters 
represent no significant differences and different letters represent significant 
differences (P < 0.05) (one-way analysis of variance). (D,F) DAT-dependent 6-
OHDA-induced cell death in both cellular models. Data are presented as mean 
± SD of four independent experiments, each carried out in triplicates (n=4). *P < 
0.05 (Student’s t-test) 
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